Amicogen Inc
Amicogen, Inc. operates as an industrial biotechnology company in South Korea and internationally. The company develops, produces, and sells of enzymes and new materials; and produces food-related additives and health functional food. It manufactures and sells of biopharmaceutical materials and resins for purifying pharmaceutical proteins and health and beauty products. In addition, the company o… Read more
Amicogen Inc (092040) - Total Assets
Latest total assets as of September 2025: ₩240.57 Billion KRW
Based on the latest financial reports, Amicogen Inc (092040) holds total assets worth ₩240.57 Billion KRW as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Amicogen Inc - Total Assets Trend (2014–2024)
This chart illustrates how Amicogen Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Amicogen Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Amicogen Inc's total assets of ₩240.57 Billion consist of 29.9% current assets and 70.1% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩6.09 Billion | 0.0% |
| Accounts Receivable | ₩7.30 Billion | 2.5% |
| Inventory | ₩10.50 Billion | 3.6% |
| Property, Plant & Equipment | ₩165.86 Billion | 56.4% |
| Intangible Assets | ₩11.35 Billion | 3.9% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2014–2024)
This chart illustrates how Amicogen Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Amicogen Inc's current assets represent 29.9% of total assets in 2024, a decrease from 56.0% in 2014.
- Cash Position: Cash and equivalents constituted 0.0% of total assets in 2024, down from 15.9% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, an increase from 2.0% in 2014.
- Asset Diversification: The largest asset category is property, plant & equipment at 56.4% of total assets.
Amicogen Inc Competitors by Total Assets
Key competitors of Amicogen Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Amicogen Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Amicogen Inc generates 0.59x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Amicogen Inc is currently not profitable relative to its asset base.
Amicogen Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.54 | 0.92 | 1.56 |
| Quick Ratio | 0.38 | 0.59 | 1.06 |
| Cash Ratio | 0.00 | 0.08 | 0.00 |
| Working Capital | ₩-36.79 Billion | ₩ -13.60 Billion | ₩ 39.47 Billion |
Amicogen Inc - Advanced Valuation Insights
This section examines the relationship between Amicogen Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.70 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -37.0% |
| Total Assets | ₩294.23 Billion |
| Market Capitalization | $51.79 Million USD |
Valuation Analysis
Below Book Valuation: The market values Amicogen Inc's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Amicogen Inc's assets decreased by 37.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Amicogen Inc (2014–2024)
The table below shows the annual total assets of Amicogen Inc from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩294.23 Billion | -37.01% |
| 2023-12-31 | ₩467.10 Billion | +8.72% |
| 2022-12-31 | ₩429.65 Billion | +4.48% |
| 2021-12-31 | ₩411.22 Billion | +45.12% |
| 2020-12-31 | ₩283.37 Billion | +17.38% |
| 2019-12-31 | ₩241.40 Billion | +4.41% |
| 2018-12-31 | ₩231.21 Billion | +41.40% |
| 2017-12-31 | ₩163.51 Billion | +11.74% |
| 2016-12-31 | ₩146.33 Billion | -8.45% |
| 2015-12-31 | ₩159.84 Billion | +194.01% |
| 2014-12-31 | ₩54.37 Billion | -- |